

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Title: Does vitamin D supplementation reduce COVID-19 severity? - a systematic review**

Author: Komal Shah<sup>1</sup>, Varna VP<sup>2\*</sup>, Ujeeta Sharma<sup>2</sup>, Dileep Mavalankar<sup>3</sup>

<sup>1</sup>Assistant Professor, Indian Institute of Public Health Gandhinagar - 382042, Gujarat, India

<sup>2</sup>MPH Student, Indian Institute of Public Health Gandhinagar - 382042, Gujarat, India

<sup>3</sup>Director, Indian Institute of Public Health Gandhinagar - 382042, Gujarat, India

**Dr. Varna V.P (\*Corresponding Author)**

<sup>2</sup>MPH Student  
Indian Institute of Public Health - Gandhinagar  
Opp. Air Force Head Quarters, Nr. Lekawada Bus Stop,  
Gandhinagar-Chiloda Road, Gandhinagar - 382042  
Mob: 9544415304  
Email: [varnavalavil@gmail.com](mailto:varnavalavil@gmail.com)

**Abstract:**

**Background and Aim:** The evidence regarding the efficacy of vitamin D supplementation in reducing severity of COVID-19 is still insufficient. This is partially due to the lack of primary robust trial-based data and heterogenous study designs. This evidence summary, aims to study the effect of vitamin D supplementation on morbidity and mortality in hospitalized COVID-19 patients.

**Methods:** For this study, systematic reviews and meta-analysis published from December 2019 to January 2022 presenting the impact of vitamin D supplementation on COVID-19 severity were screened and selected from PubMed and Google scholar. After initial screening, 10 eligible reviews were identified and quality of included reviews were assessed using AMSTAR and GRADE tools and overlapping among the primary studies used were also assessed.

**Results:** The number of primary studies included in the systematic reviews ranged from 3-13. Meta-analysis of seven systematic reviews showed strong evidence that vitamin D supplementation reduces the risk of mortality (Odds ratio: 0.48, 95% CI: 0.346-0.664;  $p < 0.001$ ) in COVID patients. It was also observed that supplementation reduces the need for intensive care (Odds ratio: 0.35; 95%CI: 0.28-0.44;  $p < 0.001$ ) and mechanical ventilation (Odds ratio: 0.54; 95% CI: 0.411-0.708;  $p < 0.001$ ) requirement. The findings were robust and reliable as level of heterogeneity was considerably low. Qualitative analysis showed that supplements (oral and IV) are well tolerated, safe and effective in COVID patients.

**Conclusion:** Findings of this study shows that vitamin D supplementation is effective in reducing COVID-19 severity. Hence vitamin D should be recommended as an adjuvant therapy for COVID-19.

**Keywords:** Vitamin D, COVID-19, Evidence synthesis, mortality, Intensive care unit, Ventilation

1

2

3

4

5

35     **Introduction**

6

7

8

9

10

11

12

13

14

15

16

17

18

36     With the new variant OMICRON, the world is again witnessing a huge surge in COVID-19 cases.  
37     It is observed that the viral genome has undergone significant changes this time, resulting in  
38     a multiple fold increase in infectivity and strengthened immune invasion. Many countries  
39     reported a sharp spike in the cases, almost doubling in just over a day.<sup>1</sup> With vaccine inequity and  
40     hesitancy, experts are already predicting that there might be emergence of new variants. So, it is  
41     need of the hour to envisage effective economic treatment strategies, as developing new vaccines  
42     for every variant cannot be economically viable or technically feasible solution.

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

43     In the midst of the unregulated usage of multiple costlier and mildly effective drug molecules,  
44     vitamin-D remains an understudied and underused treatment strategy for COVID-19. Vitamin-D  
45     is an immune modulator known to protect from acute respiratory tract infections.<sup>2</sup> The protective  
46     effect of vitamin D is exerted through multiple mechanisms such as modulation of ACE-2 receptor  
47     activity, triggering of innate and adaptive immune responses and reducing the levels of cytokines.  
48     SARS-CoV-2 is known to initiate a cascade of inflammatory reactions where acute phase  
49     biomarkers levels are elevated. This leads to COVID-19 acute respiratory distress syndrome  
50     (ARDS).<sup>3</sup> So similar to other respiratory tract diseases, studies have also explored the potential  
51     role of vitamin D supplementation on reducing COVID-19 associated morbidity and mortality.  
52     Few randomized controlled trials (RCTs) have shown that, with various doses and forms of vitamin  
53     D, risk of hospitalization, need for mechanical ventilation and intensive care unit (ICU) admission  
54     can be reduced significantly.<sup>4-7</sup> Similarly, the rate of morbidity and mortality was considerably  
55     high in COVID positive patients having vitamin D deficiency as compared to patients with normal  
56     levels of vitamin D.<sup>8-11</sup> However, RCTs showing improvement in the mortality rate with vitamin  
57     D supplementation remains non-significant, majorly due to smaller sample size and lower  
58     incidence of mortality in the study participants.<sup>12</sup> In contrast there was another study that  
59     documented a positive impact on mortality with vitamin D supplementation.<sup>13</sup>

49

50

51

52

53

54

55

56

60

61

62

63

60     Despite these promising initial outcomes, integration of vitamin D in preventive or treatment  
61     guidelines for COVID-19 has not been recommended by any government agencies or WHO. This  
62     could be possibly due to 1) lack of evidence from RCTs with larger sample size 2) Heterogeneity  
63     with respect to design, drug dosage and population characteristics that have been observed in

reported studies 3) difference of opinion among clinicians regarding its effectiveness 4) lack of clarity about the influence of various confounders such as ethnicity, race, age, gender and comorbidity on vitamin D effectiveness. This points to the fact that a uniform methodology is required in order to reach a final conclusion on vitamin D utility.

Hence this current evidence summary is designed to generate evidence towards the potential use of vitamin D supplementation in reducing mortality, intensive care unit (ICU) admissions and the reduction in use of ventilation in hospitalized COVID-19 patients.

## **Methods**

The current review was conducted in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).

### ***Inclusion and exclusion criteria***

We included systematic reviews that studied the effect of vitamin D supplementation on three outcomes – ventilation, ICU admissions, and mortality. Articles published in languages other than English were excluded from the review. Reports that studied the effect vitamin D deficient or replete individuals, on COVID-19 associated mortality and length of hospital stay were excluded.

### ***Search strategy***

Articles from December 2020 to January 2022 were screened for the review by two independent reviewers (US and VP) using the following MeSH terms: COVID-19, Coronavirus disease, SARS-CoV2, Coronavirus, Vitamin D supplementation, Vit D, vitamin D supplements, mortality, death, ICU admission, ICU stay, ventilation, mechanical ventilation, COVID-19 outcomes. These search terms were connected using boolean operators (AND, OR, NOT). Additionally, reference tracking of the searched articles was carried out to identify other relevant articles that were missed during the initial search. We excluded duplicate studies from the final search.

### ***Data extraction***

The full text of the selected articles was analyzed by three independent reviewers. Qualitative and quantitative data from each study was extracted into an excel sheet. Details of authors, publication dates and country, number of included studies, sample size, vitamin D supplementation and its impact on ICU admissions, ventilation requirement and mortality in COVID patients were

1  
2  
3 92 extracted from the selected systematic reviews. Quantitative information was used to conduct a  
4  
5 93 meta-analysis and qualitative information regarding key findings, strengths and limitations of the  
6  
7 94 studies were noted from each review. Disagreements regarding any of the information to be  
8  
9 95 extracted was resolved by discussion and mutual agreement.

10  
11 96 ***Quality assessment***  
12  
13

14 97 All the included systematic reviews were assessed for risk of bias using AMSTAR (A  
15  
16 98 Measurement Tool to Assess Systematic Reviews to assess the methodological quality of review  
17  
18 99 and meta-analysis) tool. Based on the assessed risk of bias the articles were grouped into high,  
19 100 moderate, low and critically low-quality studies. The quality of included reviews was assessed  
20  
21 101 using GRADE (Grading of Recommendations Assessment, Development, and Evaluation)  
22  
23 102 classification.

24  
25 103 ***Data synthesis***  
26  
27

28 104 Data from each selected systematic review were abstracted into evidence tables and a meta-  
29  
30 105 analysis was performed for seven studies using quantitative data provided by individual studies.  
31  
32 106 Heterogeneity of between-study variance was assessed using Cochrane’s Q test ( $p < 0.10$ ) and  
33  
34 107 quantified using the  $I^2$  statistics.  $I^2 > 50\%$  and a  $p < 0.05$  were considered substantial heterogeneity.  
35  
36 108 Heterogeneity in the results was analyzed using Q statistics (significant at  $p < 0.10$ ).  $I^2$  – a  
37  
38 109 quantitative measure of heterogeneity was used to categorize studies into various levels of  
39  
40 110 heterogeneity (high: 75–100%, medium: 50–70%, and low: 0–50%). In case of  $I^2$  more than 50%,  
41  
42 111 a random-effect model was considered to measure the impact of an intervention, whereas fixed  
43  
44 112 effect model was applied for the cases having  $I^2$  less than 50%. All statistics were performed using  
45  
46 113 Medcalc version 20.026. Publication bias was assessed using Begg’s test and Egger’s test.  
47  
48 114 Presence or absence of a statistically significant bias was concluded from the quantitative results  
49  
50 115 of Egger’s and Begg and Mazumdar rank correlation test, whereas visual inspection of bias was  
51  
52 116 undertaken using a Funnel plot.

53  
54 117 **Results**  
55

56 118 Systematic reviews and meta-analysis published from the beginning of pandemic till January 2022  
57  
58 119 were screened for this study. The reviews comparing effect of vitamin D supplementation on  
59  
60

mortality rates, ICU admission and ventilation requirement among COVID positive cases as compared to placebo or routine treatment were studied in detail. An initial search in PubMed and Google scholar using the search strategy yielded 10,221 articles. Finally, 10 articles meeting the inclusion criteria were analyzed for the review.<sup>14–23</sup>

Characteristic details of all the included systematic reviews were extracted and are presented in Table 1. The number of primary studies included in the reviews ranged from 3–13, which included all types of study designs including randomized controlled trials. Latest review was published in December 2021. Hence it seems that most studies were done before the appearance of Omicron variant. Three reviews were conducted from India.

Most of the studies considered for this evidence summary have used vitamin D supplementation in oral form either as oral cholecalciferol or oral calcifediol.<sup>15,17–19,23</sup> The dosage of the supplementation varied in the studies. Booster therapies given were in the range of 280,000 IU or 400,000 IU.<sup>18</sup> Upon careful evaluation, a unique study based on ethnicity found out that vitamin D3 is more efficacious than D2, when supplemented orally. The lowest dose administered was 400 IU while 60,000 IU was the highest.<sup>23</sup> Another study by Nikniaz L et al supplemented the intervention group with oral vitamin D3 (60,000 IU– 80,000IU). The conclusion drawn from the study supported that vitamin D supplementation was more efficacious against mortality when compared to corticosteroids, hydroxychloroquine and other antibiotics.<sup>17</sup>

AMSTAR and GRADE assessment showed that majority of the systematic reviews were suffering from low quality of evidences (Supplementary table 1 and 2). Significant heterogeneity was observed among the studies reporting efficacy of vitamin D on morbidity and mortality outcomes in COVID patients. Majority of the studies showed improvement in the outcome, however due to smaller sample size, some studies could not reach to a statistically significant level. The strength, limitations and key findings of the individual review are summarized in table 2. Overlapping between the primary studies included in the systematic reviews were also assessed and considerable overlapping was observed. The individual study level analysis is presented as supplementary table 3.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Mortality**

A meta-analysis of seven systematic reviews, providing quantitative data regarding the odds of mortality among hospitalized COVID-19 patients with and without vitamin D supplementation was performed. It was found that, in people receiving vitamin D supplements, the odds of mortality were 52% lower as compared to individuals not receiving vitamin D supplements. (OR: 0.48, 95% CI: 0.346-0.664;  $p<0.001$ ) (figure 2). This suggests that vitamin D supplementation acts as a protective therapy in reducing overall COVID-19 related mortality. Random effect model was considered due to presence of heterogeneity ( $I^2=54\%$ ;  $p=0.04$ ) among the review findings.

**ICU admission**

The cumulative effect of vitamin D supplementation on risk of ICU admission in COVID-19 hospitalized patients were assessed using meta-analysis of seven number of systematic reviews. It was observed that there is a statistically significant ( $P < 0.0001$ ) difference between ICU admission rate in patients receiving vitamin D supplements as compared to patients not receiving vitamin D. The odds of intensive care needs were 0.35 (95%CI: 0.28-0.44) with vitamin D supplementation (figure 3). The findings were robust and reliable with absence of heterogeneity as indicated by  $I^2$  (0%;  $P = 0.78$ ).

**Ventilation**

Three studies provided quantitative data regarding effect of vitamin D supplementation on requirement of mechanical ventilation in COVID patients.<sup>16,19,21</sup> Pooled analysis showed that there is a reduction in odds of requiring ventilation support in patients treated with vitamin D supplementation as compared to others without vitamin D treatment (Odds ratio: 0.54; 95% CI: 0.411-0.708;  $p<0.001$ ) (figure 4). Fixed effect model was considered as no heterogeneity was noted as per  $I^2$  statistics (0%;  $p=0.94$ ).

**Discussion**

The current evidence summary presents findings from 10 published systematic reviews studying the effect of vitamin D supplementation on morbidity and mortality in hospitalized COVID-19 patients.<sup>14–23</sup> The review attempted to synthesize both qualitative and quantitative evidence from

the published articles through a systematic approach and observed that vitamin D supplementation reduces the risk of mortality, need for intensive care and ventilation in COVID-19 patients irrespective of age, gender, race, ethnicity and comorbid conditions. These studies were from India, China, Indonesia, Greece, the United Kingdom, and Germany, spanning a large geographical area.

Vitamin D and COVID-19, desirable levels of vitamin D in the serum and the recommended doses of supplementation has been in the spot-light and are still under dialogue among the medical fraternity. However, with the rise of OMICRON and the possibility of future waves of the coronavirus, it is critical to investigate all possible COVID-19 management and treatment options. With low cost of vitamin D, easy availability in global pharmaceutical market, good safety at least at a dosage of 4000 IU/day, familiarity of clinicians with the molecule and its mechanism of action and well prevalent deficiency in the population makes it a very suitable drug for COVID management even with controversial efficacy.<sup>24</sup> Findings of the present evidence summary overcomes some of the inherent limitations associated with vitamin D supplementation trials and showed that vitamin D can be advocated as a possible adjunctive for the management of at least hospitalized COVID-19 patient.

Use of vitamin-D supplementation to prevent acute respiratory tract infections has already been documented by various clinical trials and systematic reviews.<sup>5–7,16,18–20,22</sup> The mode of cellular action of vitamin D<sub>3</sub> receptors especially in T cells and dendritic cells make it suitable for the treatment of COVID-19 disease<sup>25</sup>. Also, vitamin D cathelicidins are known to promote autophagy and have anti-viral properties. Use of this antimicrobial peptide (human cathelicidin LL-37) can inhibit SARS-Cov-2 infection.<sup>26–28</sup> Rationally, all these factors together became the underlying biological foundation for using vitamin D in the present pandemic. However, the impact of supplementation varies from being modest to large as indicated in evidence synthesis report.

The evidence summary consisted of systematic reviews involving as small as three primary trials to 13 trials and have presented entire landscape assessment right from starting of the pandemic. It also presents the impact of vitamin D on patients with entire spectrum of disease severity which showed mixed evidence. From all the systematic reviews identified for this summary synthesis, the review with the largest sample size of 5,36,418 participants concluded that low vitamin D



1  
2  
3 204 levels do not exacerbate COVID-19 risk and nor does vitamin D supplementation improve  
4  
5 205 outcomes in hospitalized patients with COVID-19.<sup>14</sup> In contrast, studies such as those conducted  
6  
7 206 in India using adjunctive pulse D therapy (60000IU) in combination with the standard treatments  
8  
9 207 for COVID-19 concluded that vitamin D was a potential immunomodulator that could be added to  
10  
11 208 the COVID-19 treatment protocol. Furthermore, a trial involving 76 participants found  
12  
13 209 that calcifediol at a high dose helped significantly reduce ICU admissions.<sup>4</sup>  
14  
15 210 A systematic review involving Asian ethnicities revealed that vitamin D supplementation at a  
16  
17 211 dosage of 400IU is more effective at raising 25(OH)D levels when sun exposure does not permit  
18  
19 212 sufficient vitamin D synthesis in black and Asian ethnicities.<sup>23</sup> The study found that whereas  
20  
21 213 25(OH)D levels were 25 nmol L<sup>-1</sup> at baseline, vitamin D supplementation, independent of dosage,  
22  
23 214 mode of delivery, or duration, boosted the levels to >25 nmol L<sup>-1</sup>. It was worth mentioning that the  
24  
25 215 mode of vitamin D ingestion played a significant influence in boosting serum 25(OH)D levels.<sup>29</sup>  
26  
27 216 Due to climatic conditions, people in the temperate zone are usually less exposed to the sun,  
28  
29 217 whereas Asians and Africans suffer from vitamin D insufficiency due to the constitutive pigment  
30  
31 218 melanin in the skin, which absorbs UV radiation and protects the underlying tissues from  
32  
33 219 damage.<sup>30</sup>  
34  
35 220 So far, no guidelines have been established by the Centre for Disease Control or World Health  
36  
37 221 Organization on the supplementation of vitamin D as a treatment for COVID-19 outcomes.  
38  
39 222 The role of vitamin D supplementation on COVID-19 related outcomes has been studied  
40  
41 223 extensively, but it remains controversial whether vitamin D should be included as a curative in the  
42  
43 224 COVID-19 treatment guidelines. The results of multiple studies, including randomized control  
44  
45 225 trials (RCTs), offer mixed evidence and hence, we have excluded reviews that do not meet the  
46  
47 226 highest standards of evidence. This adds strength to the current summary of evidence.  
48  
49 227 Findings from quantitative analysis presented as meta-analysis in this review addresses one  
50  
51 228 important limitation of the individual systematic reviews – low sample size and presence of  
52  
53 229 heterogenous data. But the cumulative analysis of the included reviews suggests that vitamin D  
54  
55 230 has the potential to prevent and treat COVID-19-related outcomes, such as mortality, ICU  
56  
57 231 admissions, and ventilation. We also acknowledge that there was a high overlap between the  
58  
59  
60

included studies in the reviews. Hence, with this review we aim to advocate the integration of vitamin D supplementation in the treatment protocol for COVID-19.

## Conclusion

The current evidence suggests that vitamin D is a potential immunomodulator that has a major role in lowering COVID-19-related mortality, ICU hospitalizations, and ventilation. As a result, we believe that supplementary vitamin D can be safely added to the existing COVID-19 treatment procedures.

## References

1. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Available from: [www.nature.com/nrmicro](http://www.nature.com/nrmicro)
2. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data Supplementary Material Davaasambuu Ganmaa 7 Adit A Ginde 8 Ilkka Laaksi 13 Semira Manaseki-Holland 14 Iwona Stelmach. 2017.
3. Malaguarnera L. Vitamin D3 as Potential Treatment Adjuncts for COVID-19. *Nutrients* [Internet]. 2020;12. Available from: [www.mdpi.com/journal/nutrients](http://www.mdpi.com/journal/nutrients)
4. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study." *J Steroid Biochem Mol Biol*. 2020;203(August 2020).
5. Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad Med J* [Internet]. 2020; Available from:

1  
2  
3 258 <http://pmj.bmj.com/>  
4  
5  
6 259 6. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a  
7  
8 260 Single High Dose of Vitamin D3on Hospital Length of Stay in Patients with Moderate to  
9  
10 261 Severe COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc.  
11 262 2021;325(11):1053–60.  
12  
13  
14 263 7. Han JE, Jones JL, Tangpricha V, Brown MA, Hao L, Hebbar G, et al. High dose Vitamin  
15 264 D administration in ventilated intensive care unit patients: A pilot double blind  
16  
17 265 randomized controlled trial. J Clin Transl Endocrinol [Internet]. 2016;4:59–65. Available  
18  
19 266 from: <http://dx.doi.org/10.1016/j.jcte.2016.04.004>  
20  
21  
22 267 8. Mercola J, Grant WB, Wagner CL. Evidence Regarding Vitamin D and Risk of COVID-  
23 268 19 and Its Severity. Available from: [www.mdpi.com/journal/nutrients](http://www.mdpi.com/journal/nutrients)  
24  
25  
26 269 9. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin  
27  
28 270 D Deficiency and Outcome of COVID-19 Patients. 2020; Available from:  
29  
30 271 [www.mdpi.com/journal/nutrients](http://www.mdpi.com/journal/nutrients)  
31  
32 272 10. Campi I, Gennari L, Merlotti D, Mingiano C, Frosali A, Giovanelli L, et al. Vitamin D  
33  
34 273 and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect  
35  
36 274 Dis. 2021;21(1):1–13.  
37  
38  
39 275 11. Karahan S, Katkat F. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients  
40 276 with COVID-19 in Turkey. J Nutr Heal Aging. 2021;25(2):189–96.  
41  
42  
43 277 12. Shen H, Mei Y, Zhang K, Xu X. The Effect of Vitamin D Supplementation on Clinical  
44  
45 278 Outcomes for Critically Ill Patients: A Systemic Review and Meta-Analysis of  
46  
47 279 Randomized Clinical Trials. Front Nutr. 2021;8(May):1–11.  
48  
49 280 13. Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, Richards JB. The  
50  
51 281 health effects of vitamin D supplementation: evidence from human studies. Nat Rev  
52  
53 282 Endocrinol. 2022;18(2):96–110.  
54  
55 283 14. Chen J, Mei K, Xie L, Yuan P, Ma J, Yu P, et al. Low vitamin D levels do not aggravate

- COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. *Nutr J* [Internet]. 2021;20(1):1–10. Available from: <https://doi.org/10.1186/s12937-021-00744-y>
15. Grove A, Osokogu O, Al-Khudairy L, Mehrabian A, Zanganeh M, Brown A, et al. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. *BMJ Open*. 2021;11(5):1–9.
  16. Hariyanto TI, Intan D, Hananto JE, Harapan H, Kurniawan A. Vitamin D supplementation and Covid-19 outcomes: A systematic review, meta-analysis and meta-regression. *Rev Med Virol*. 2021;(June):1–13.
  17. Nikniaz L, Akbarzadeh MA, Hosseini H, Hosseini MS. The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis. *Pharm Sci*. 2021;27:S1–12.
  18. Pal R, Banerjee M, Bhadada SK, Shetty AJ, Singh B, Vyas A. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. *J Endocrinol Invest* [Internet]. 2022;45(1):53–68. Available from: <https://doi.org/10.1007/s40618-021-01614-4>
  19. Rawat D, Roy A, Maitra S, Shankar V, Khanna P, Baidya DK. “Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis.” *Diabetes Metab Syndr Clin Res Rev*. 2021;15(4).
  20. Shah K, Saxena D, Mavalankar D. Vitamin D supplementation, COVID-19 and disease severity: A meta-analysis. *Qjm*. 2021;114(3):175–81.
  21. Strohlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. *Cochrane Database Syst Rev*. 2021;2021(5).

1  
2  
3 310 22. Tentolouris N, Samakidou G, Eleftheriadou I, Tentolouris A, Jude EB. The effect of  
4 311 vitamin D supplementation on mortality and intensive care unit admission of COVID-19  
5 312 patients. A systematic review, meta-analysis and meta-regression. *Diabetes Metab Res*  
6 313 *Rev.* 2022;(November 2021).  
7  
8  
9  
10  
11 314 23. Vaughan M, Trott M, Sapkota R, Premi G, Roberts J, Ubhi J, et al. Changes in 25-  
12 315 hydroxyvitamin D levels post-vitamin D supplementation in people of Black and Asian  
13 316 ethnicities and its implications during COVID-19 pandemic: A systematic review. *J Hum*  
14 317 *Nutr Diet.* 2021;(June):1–11.  
15  
16  
17  
18  
19 318 24. Rizzoli R. Vitamin D supplementation: upper limit for safety revisited? *Aging Clin Exp*  
20 319 *Res [Internet].* 2021;33:19–24. Available from: [https://doi.org/10.1007/s40520-020-](https://doi.org/10.1007/s40520-020-01678-x)  
21 320 [01678-x](https://doi.org/10.1007/s40520-020-01678-x)  
22  
23  
24  
25 321 25. Griffin G, Hewison M, Hopkin J, Kenny R, Quinton R, Rhodes J, et al. Vitamin D and  
26 322 COVID-19: Evidence and recommendations for supplementation. *R Soc Open Sci.*  
27 323 2020;7(12).  
28  
29  
30  
31 324 26. Wang C, Wang S, Li D, Chen P, Han S, Zhao G, et al. Human Cathelicidin Inhibits  
32 325 SARS-CoV-2 Infection: Killing Two Birds with One Stone. *ACS Infect Dis.*  
33 326 2021;7(6):1545–54.  
34  
35  
36  
37 327 27. Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: An evidence-based  
38 328 review. *J Am Board Fam Med.* 2009;22(6):698–706.  
39  
40  
41  
42 329 28. Chung C, Silwal P, Kim I, Modlin RL, Jo EK. Vitamin D-cathelicidin axis: At the  
43 330 crossroads between protective immunity and pathological inflammation during infection.  
44 331 *Immune Netw.* 2020;20(2):1–26.  
45  
46  
47  
48 332 29. Grønborg IM, Tetens I, Christensen T, Andersen EW, Jakobsen J, Kiely M, et al. Vitamin  
49 333 D-fortified foods improve wintertime vitamin D status in women of Danish and Pakistani  
50 334 origin living in Denmark: a randomized controlled trial. *Eur J Nutr* 2019 592 [Internet].  
51 335 2019 Mar 9 [cited 2022 Feb 1];59(2):741–53. Available from:  
52 336 <https://link.springer.com/article/10.1007/s00394-019-01941-6>  
53  
54  
55  
56  
57  
58  
59  
60

- 337 30. Webb AR, Kazantzidis A, Kift RC, Farrar MD, Wilkinson J, Rhodes LE. Colour Counts:  
338 Sunlight and Skin Type as Drivers of Vitamin D Deficiency at UK Latitudes. *Nutrients*  
339 [Internet]. 2018; Available from: [www.mdpi.com/journal/nutrients](http://www.mdpi.com/journal/nutrients)

340

**Table 1: Basic characteristics of the included systematic reviews**

Serial Number	Authors	Title	Country	No of studies included	Types of studies included	Total Population
1	Chen J et al, Oct 2012 <sup>14</sup>	Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: A meta-analysis and GRADE assessment of cohort studies and RCTs	China	13	Cohort studies=11, Randomised control Trials=2	5,36,418
2	Grove A et al, May 2021 <sup>15</sup>	Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review	UK	4	Cross-sectional study=1, retrospective cohort study=1, ecological country study=1, case-control survey=1	2042
3	Hariyanto TI et al, June 2021 <sup>16</sup>	Vitamin D supplementation and Covid-19 outcomes: A systematic review, meta-analysis and meta-regression	Indonesia	11	Retrospective cohort studies=4, Open-label randomised clinical trial=1, Prospective cohort studies=2, Cross sectional studies=3, double-blind randomised clinical trial=1	2265

4	Nikniaz L et al, Jan 2021 <sup>17</sup>	The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis	Iran	4	Randomised Control Trials=2, Quasi Experimental trials=2	259
5	Pal R et al, June 2021 <sup>18</sup>	Vitamin D supplementation and clinical outcomes in COVID 19: a systematic review and meta-analysis	India	13	Randomised control trials=3, Observational studies=10	2933
6	Rawat D et al, June 2021 <sup>19</sup>	Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis	India	5	Randomised control trials=3, Quasi experimental studies=2	467
7	Shah K et al, May 2021 <sup>20</sup>	Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis	India	3	Randomised control trials=2, retrospective case-control study=1	532
8	Stroehlein et al, May 2021 <sup>21</sup>	Vitamin D supplementation for the treatment of COVID-19: a living systematic review	Germany	3	Randomised Control Trials=3	356
9	Tentolouris N et al, Dec 2021 <sup>22</sup>	The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression	Greece	10	Randomised control trials=2, non-randomised trials=8	2078



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


10	Vaughan M et al, Oct 2021 <sup>23</sup>	Changes in 25-hydroxyvitamin D levels post-vitamin D supplementation in people of Black and Asian ethnicities and its implications during COVID-19 pandemic: A systematic review	UK	8	Randomised Control Trials=8	1108
----	---	---	----	---	-----------------------------------	------

**Table 2: Findings of the included systematic reviews**

Serial Number	Authors	Key Findings	Strength	Limitations
1	Chen J et al, Oct 2012 <sup>14</sup>	No significant association of Vitamin-D deficiency/insufficiency with COVID-19 infections, mortality and ICU admissions.	Study design which includes cohort studies and Randomized control trials. Use of GRADE to evaluate the quality of evidence.	High heterogeneity due to study design and baseline characteristics. Potential risk factors were not completely adjusted.
2	Grove A et al, May 2021 <sup>15</sup>	No robust evidence to assess the association of Vitamin-D supplementation with COVID-19 and its outcomes such as mortality, morbidity.	Study design using PRISMA checklist and information on current situation using multiple living systematic review data bases	Study design which consisted of non-randomised studies. Small amount of evidence that might led to bias and hence the inferences that can be drawn.
3	Hariyanto TI et al, June 2021 <sup>16</sup>	Association of Vitamin-D with reduction in ICU admission, mortality and mechanical ventilation. Age is associated with Vitamin-D supplementation and COVID-19 mortality.	The potential of Vitamin-D as a favourable drug to reduce the clinical outcomes of COVID-19.	Significant heterogeneity due to the prescribed doses and co-administered drugs with Vitamin-D.
4	Nikniaz L et al, Jan 2021 <sup>17</sup>	Pooled estimations showed a significant reduction in mortality, severity of disease and serum levels of inflammatory markers upon Vitamin-D supplementation as compared to the control group.	Careful evaluation of the vitamin-D supplementation on mortality rates, ICU admission as well as the secondary outcomes such as reduction in severity of disease using WHO OSCI score.	Ineffective to standardise the optimum dosage and route of administration.
5	Pal R et al, June 2021 <sup>18</sup>	Vitamin-D is significantly associated with COVID-19 in terms of reducing	The strength of this study lies in the fact that it reflects	Appropriate Dose, duration and mode of administration yet

		mortality, ICU admissions and other clinical outcomes.	the benefits of Vitamin-D supplementation only in COVID-19 positive population.	could not be answered.
	Rawat D et al, June 6 2021 <sup>19</sup>	No significant association is seen between Vitamin-D supplementation in reducing the clinical outcomes such as mortality, ICU admission and ventilation.	Observations drawn on the basis of RCT'S and Quasi Experimental Trials.	The number of studies undertaken were less to arrive to a final conclusion. Time frame was also not considered. Heterogeneity in intervention with respect to Vitamin-D supplementation. Significant non-uniformity with regards to various factors in Vitamin-D supplementation.
	Shah K et al, May 7 2021 <sup>20</sup>	Association between Vitamin-D supplementation in reducing ICU requirements, but almost same effects in mortality as placebo.	First meta-analysis that showed the positive association of Vitamin-D supplementation in reducing the clinical outcomes such as ICU requirements.	Heterogenous baseline populations that were enrolled, Number of trials that took place while the study was being conducted.
	Stroehlein et al, May 8 2021 <sup>21</sup>	Limited safety information to usage of Vitamin-D supplementation for COVID-19 population.	A living approach were based on the current findings and on-going literature data was published.	No pooling of data due to heterogeneity of the studies, leading to uncertainty if Vitamin-D can be potentially used for reducing all-cause mortality in Covid-19 population.
	Tentolouris N et al, Dec 9 2021 <sup>22</sup>	No significant linear relationship observed between Vitamin-D supplementation and	A meta-regression analysis regarding the relationship between the	Inclusion of non-randomized studies. Heterogeneity in the

		mortality, although it has a reduced effect on ICU admissions	administered dose of vitamin-D and the outcome of interest.	study in forms of dose.
10	Vaughan M et al, Oct 2021 <sup>23</sup>	Vitamin D3 is more efficacious than Vitamin-D, oral supplementation is more effective in black and Asian people.	Form and Route of administration that can be more beneficial in context of ethnicities.	Heterogeneity in studies in terms of dosage, duration and populations. Only English studies were included which could be translated.



PRISMA chart


180x252mm (300 x 300 DPI)



Forest plot showing the effect of Vitamin D supplementation on mortality

Forest plot showing the effect of vitamin D supplementation on mortality


324x114mm (118 x 118 DPI)



Forest plot showing the effect of Vitamin D supplementation on ICU requirement

Forest plot showing the effect of vitamin D supplementation on ICU admissions

302x93mm (118 x 118 DPI)



Forest plot showing the effect of Vitamin D supplementation on ventilation requirement

Forest plot showing the effect of vitamin D supplementation on ventilation requirement

324x92mm (118 x 118 DPI)